These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 17977894)

  • 1. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
    Habib-Agahi M; Phan TT; Searle PF
    Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
    Habib-Agahi M; Jaberipour M; Searle PF
    Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28- T cells.
    Park W; Weyand CM; Schmidt D; Goronzy JJ
    Eur J Immunol; 1997 May; 27(5):1082-90. PubMed ID: 9174596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86.
    Habib-Agahi M; Jaberipour M; Phan TT; Searle PF
    Iran J Immunol; 2008 Sep; 5(3):136-47. PubMed ID: 18791280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2.
    Mukherjee S; Ahmed A; Malu S; Nandi D
    J Leukoc Biol; 2006 Jul; 80(1):66-74. PubMed ID: 16624934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells.
    Wolthers KC; Otto SA; Lens SM; Kolbach DN; van Lier RA; Miedema F; Meyaard L
    Eur J Immunol; 1996 Aug; 26(8):1700-6. PubMed ID: 8765009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
    Mukherjee S; Ahmed A; Nandi D
    J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.
    Lanier LL; O'Fallon S; Somoza C; Phillips JH; Linsley PS; Okumura K; Ito D; Azuma M
    J Immunol; 1995 Jan; 154(1):97-105. PubMed ID: 7527824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct effects of CD86-mediated costimulation on resting versus activated human CD4+ T cells.
    Rogers NJ; Game DS; Camara NO; Jackson IM; Lombardi G; Lechler RI
    Eur J Immunol; 2005 Oct; 35(10):2909-19. PubMed ID: 16180251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of costimulatory molecules CD80 and/or CD86 by a Kaposi's sarcoma tumor cell line induces differential T-cell activation and proliferation.
    Foreman KE; Wrone-Smith T; Krueger AE; Nickoloff BJ
    Clin Immunol; 1999 Jun; 91(3):345-53. PubMed ID: 10370381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium.
    Wang P; Liu Z; Wu C; Zhu B; Wang Y; Xu H
    Transplant Proc; 2008 Oct; 40(8):2729-33. PubMed ID: 18929847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
    Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
    Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
    McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
    Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
    J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
    Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
    J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CD80 and CD86 in enhancing CD8(+) cell suppression of HIV replication.
    Barker E; Bossart KN; Fujimura SH; Levy JA
    Cell Immunol; 1999 Sep; 196(2):95-103. PubMed ID: 10527561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand.
    Gramaglia I; Cooper D; Miner KT; Kwon BS; Croft M
    Eur J Immunol; 2000 Feb; 30(2):392-402. PubMed ID: 10671194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis.
    Ohki O; Yokozeki H; Katayama I; Umeda T; Azuma M; Okumura K; Nishioka K
    Br J Dermatol; 1997 Jun; 136(6):838-45. PubMed ID: 9217814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.